Condition
HR-positive, HER2-negative, inoperable locally advanced or metastatic breast cancer
Total Trials
1
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Oral Femara Ribociclib Injectable Placebo
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
100%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 3 (1)
Trial Status
Not Yet Recruiting1
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Oral Femara Ribociclib Injectable Placebo1
- Letrozole Sie Ribociclib Oral Placebo1
Active Sponsors
- Rovi Pharmaceuticals Laboratories1
- Laboratorios Farmaceuticos Rovi S.A.1
Related Conditions
- Advanced Metastatic Breast Cancer1